Karuna Therapeutics

Top biotech licensing deals of Q1 2023
Top biotech licensing deals of Q1 2023
BioSpace
biotech
licensing
Moderna Therapeutics
CytomX
Voyager Therapeutics
Neurocrine Biosciences
Kronos Bio
Genentech
Karuna Therapeutics
Goldfinch Bio
Flag link:
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
Flag link:
JPM Day 2: Highlights
JPM Day 2: Highlights
BioSpace
JPMHC 2023
Relay Therapeutics
Sanofi
Scholar Rock
SAGE Therapeutics
Karuna Therapeutics
GSK
Flag link:
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Flag link:
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
Flag link:
3 Biopharmas on Buyout Watch
3 Biopharmas on Buyout Watch
Motley Fool
M&A
Axsome Therapeutics
Alnylam Pharmaceuticals
Karuna Therapeutics
Flag link:
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Karuna’s resurrection of Lilly drug delivers phase 3 schizophrenia success, teeing up 2023 filing
Fierce Biotech
Karuna Therapeutics
clinical trials
schizophrenia
KarXT
Flag link:
Karuna seeks a novel schizophrenia mechanism
Karuna seeks a novel schizophrenia mechanism
EP Vantage
Karuna Therapeutics
antipsychotics
schizophrenia
KarXT
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
Karuna and Incyte scrap programs; More cash for the SPACs
Karuna and Incyte scrap programs; More cash for the SPACs
Endpoints
Karuna Therapeutics
Eli Lilly
Incyte
SPAC
Flag link:
Karuna Therapeutics Files for $52 Million Offering
Karuna Therapeutics Files for $52 Million Offering
CP Wire
Karuna Therapeutics
schizophrenia
KarXT
Flag link:
Karuna Therapeutics Files for $52 Million Offering
Karuna Therapeutics
schizophrenia
psychosis
KarXT
Flag link:
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Benzinga
Karuna Therapeutics
schizophrenia
clinical trials
KarXT
Flag link:
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
CP Wire
Karuna Therapeutics
IPOs
schizophrenia
Alzheimer's disease
Flag link: